CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Speaker 1: Good afternoon, everyone. Thank you for standing by. Welcome to the Cytomex Therapeutics 3rd 0.25 2025 Speaker 1: financial results call. Please be advised that today's call is being recorded. Speaker 1: I would now like to hand the call over to your host for today, Chris Ogden, Cytomex's Speaker 1: Chief Financial Officer. Please go ahead. Speaker 2: Thank you. Good afternoon and thank you for joining us. Speaker 2: Before we begin, I'd like to remind everyone that during this call, we'll be making 4 looking statements. Speaker 2: Because 4 looking statements relate to the future, Speaker 2: they're subject to inherent uncertainties and risks that are difficult to predict and many of which are outside of our control. Speaker 2: Important risks and uncertainties are set forth in our most recent public filings Speaker 2: with the SEC at sec.gov. Speaker 2: We undertake no obligation to update any for looking statements, whether as a result of new information, future developments, or otherwise. Speaker 2: Earlier this afternoon, we issued a press release that includes a summary of our 3rd 0.25 Speaker 2: 2025 Speaker 2: financial results Speaker 2: and highlights recent progress at Citomics. Speaker 2: We encourage everyone to read today's press release and the associated materials Speaker 2: which have been filed with the SEC. Speaker 2: Additionally, the press release recording of this call and our SEC filings can be found under the investors Speaker 2: and news section of our website. Speaker 2: With me on the call today is Dr. Sean McCarthy, Cytomics' Speaker 2: Chief executive officer Speaker 2: and chairman. Speaker 2: Sean will provide an update on our pipeline and company progress before I cover the financials for the 0.25. We'll then conclude with a...